Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1235256 | 0.90 | LMNA (0.60) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL425794 | 0.88 | DAO (0.65) | DAONPSR1LMNAPPARGNCOA2 | |
| SCHEMBL6487220 | 0.82 | DAO (0.76) | DAOALDH1A1GAAHPGDPOLB | |
| SCHEMBL20370914 | 0.81 | DAO (0.73) | DAOALDH1A1GAAHPGDPOLB | |
| SCHEMBL6477476 | 0.81 | KDM4E (0.58) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL23407055 | 0.80 | NPSR1 (0.50) | DAONPSR1LMNAPPARGNCOA2 | |
| SCHEMBL19439636 | 0.80 | LMNA (0.50) | DAONPSR1LMNAPPARGNCOA2 | |
| Isothiocyanate SCHEMBL1483719 | 0.80 | DAO (0.55) | DAONPSR1LMNAPPARGNCOA2 | |
| SCHEMBL12712112 | 0.80 | CYP46A1 (0.43) | DAOLMNAALDH1A1GAAHPGD | |
| SCHEMBL12712127 | 0.80 | CYP46A1 (0.43) | DAOLMNAALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1442041-A1 | AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
| US-6599916-B2 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic acetylcholine receptor is implicated, Alzheimer's disease, pre-senile dementia (mild cognitive impairment), or senile dementia. | PHARMACIA & UPJOHN COMPANY | 2003-07-29 | — | — | US | disclosed |
| WO-2003040147-A1 | AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE__________________________________________________________________________________________________________________________ | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
| US-6500840-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-6492385-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY GLOBAL INTELLECTUAL PROPERTY | 2002-07-11 | — | — | US | disclosed |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2002015662-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | DAO 935/4885NPSR1 1074/4885LMNA 2990/4885 |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | DAO 1360/4885NPSR1 835/4885LMNA 2140/4885 |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PARK7, CYP3A7, UGT2B7 | DAO 1098/4885NPSR1 900/4885LMNA 3219/4885 |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | DAO 1360/4885NPSR1 835/4885LMNA 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.